TGFB1 and systemic sclerosis: However, treatment with SSc fibroblasts with SOCE and associated inhibitors, 2APB, SKF96365 and indomethacin, led to a selective decrease in fibrosis markers in the three groups (Fig 3A and 3B), mainly the TGF-β1, α-SMA and α-tublin.